IRADIMED CORP Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by IRADIMED CORPORATION on February 6, 2018. The report serves to announce the Company's financial results for the fourth quarter ended December 31, 2017. The Company is incorporated in Delaware and identifies as an emerging growth company.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that a press release containing these details has been issued and is attached as Exhibit 99.1.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for comparative financial analysis.
Guidance, Outlook, and Risks
The text does not include management commentary, forward-looking guidance, specific risks, or contingencies. It explicitly states that the information in Item 2.02 and the attached exhibit shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated February 6, 2018) for actual Q4 2017 financial figures.
- Verify the Company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Confirm that the press release is not deemed "filed" under Section 18 of the Exchange Act, limiting liability protections for the data contained therein.
- Check subsequent filings for any updates or corrections to the Q4 2017 results.